Zobrazeno 1 - 10
of 12
pro vyhledávání: '"D. X. Xibille Friedmann"'
Autor:
D. X. Xibille Friedmann, S. M. Carrillo Vazquez, J. González Christen, D. Vega Morales, M. Garza Elizondo, R. Hernández, J. E. Ortíz Panozo, J. L. Montiel Hernández
Publikováno v:
Annals of the Rheumatic Diseases. 81:391-392
BackgroundA significant percentage of rheumatoid arthritis (RA) patients undergoing Infliximab (IFX) or Adalimumab (ADA) treatment develop antidrug antibodies with potential negative effects over their clinical activity; however, it is unknown if the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65620ec506fc907ffedd289d05c808e3
https://doi.org/10.1136/annrheumdis-2022-eular.2365
https://doi.org/10.1136/annrheumdis-2022-eular.2365
Autor:
V. Rivera Teran, D. Vega-Morales, S. Sicsik, F. Irazoque-Palazuelos, M. A. Saavedra, J. C. Casasola, S. Carrilo, A. Peña, A. Castillo Ortiz, O. E. Muñoz-Monroy, S. Duran Barragan, A. Ramos, L. F. Valdés Corona, E. Torres Valdéz, A. Paz, E. A. Zamora-Tehozol, A. Torres, S. Mendieta, D. X. Xibille Friedmann, F. Guerrero, N. Santana, M. Vazquez, C. Zepeda, M. Rivera, K. Alvarado, D. Alpizar-Rodriguez
Publikováno v:
Annals of the Rheumatic Diseases. 81:1824.1-1824
BackgroundPatients with rheumatic diseases (RD) have a higher risk of developing infections due to disease and immunosupressor treatment factors1. Biologic disease -modifying antirheumatic drugs (bDMARD) have been associated with the development of o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dd305d654d32e63cd42b148b17f54b1
https://doi.org/10.1136/annrheumdis-2022-eular.2198
https://doi.org/10.1136/annrheumdis-2022-eular.2198
Autor:
V. Rivera Teran, D. Vega-Morales, S. Sicsik, F. Irazoque-Palazuelos, M. A. Saavedra, J. C. Casasola, S. Carrilo, A. Peña, A. Castillo Ortiz, O. E. Muñoz-Monroy, S. Duran Barragan, A. Ramos, L. F. Valdés Corona, E. Torres Valdéz, A. Paz, E. A. Zamora-Tehozol, A. Torres, S. Mendieta, D. X. Xibille Friedmann, F. Guerrero, N. Santana, M. Vazquez, C. Zepeda, M. Rivera, K. Alvarado, D. Alpizar-Rodriguez
Publikováno v:
Annals of the Rheumatic Diseases. 81:1068-1068
BackgroundRheumatic diseases prevalence and characteristics in Mexico may vary depending on the country´s region1. To acknowledge these differences is needed to develop focused strategies for early diagnosis and treatment2.ObjectivesIdentify the soc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3eb0429b88becb7f3b3cca49edc0e793
https://doi.org/10.1136/annrheumdis-2022-eular.4842
https://doi.org/10.1136/annrheumdis-2022-eular.4842
Autor:
V. Rivera Teran, D. Vega-Morales, S. Sicsik, F. Irazoque-Palazuelos, M. A. Saavedra, J. C. Casasola, S. Carrilo, A. Peña, A. Castillo Ortiz, O. E. Muñoz-Monroy, S. Duran Barragan, A. Ramos, L. F. Valdés Corona, E. Torres Valdéz, A. Paz, E. A. Zamora-Tehozol, D. X. Xibille Friedmann, F. Guerrero, N. Santana, M. Vazquez, C. Zepeda, M. Rivera, K. Alvarado, D. Alpizar-Rodriguez
Publikováno v:
Annals of the Rheumatic Diseases. 81:1836-1836
BackgroundDecrease treatment persistence in rheumatoid arthritis (RA) patients has been associated with several factors, including number of previous biological DMARDs (bDMARDs), female gender and higher disease activity or lower function at baseline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20fb07962d408667c9ccd62e1a615d69
https://doi.org/10.1136/annrheumdis-2022-eular.5000
https://doi.org/10.1136/annrheumdis-2022-eular.5000
Autor:
N. Santana, K. Alvarado, S. Sicsik, F. Guerrero, D. X. Xibille Friedmann, O. Muñoz, Domingo Marrero Miranda, S. Carrilo, A. Peña, C. F. Pacheco Tena, Aníbal Castillo, V. Rivera Teran, A. Torres, J. C. Casasola, E. Zamora, Azucena Ramos, A. Paz, David Vega-Morales, M. Vazquez, F. Irazoque-Palazuelos, M. Rivera, S. Duran Barragan, C. Zepeda, D. Alpizar-Rodriguez, J. F. Moctezuma, E. Torres, F. Aceves
Publikováno v:
Annals of the Rheumatic Diseases. 79:874-875
Background:Most autoimmune diseases are more prevalent in women. Symptom severity, disease progression, response to therapy and overall survival differ between males and females with rheumatic diseases.Objectives:To identify the characteristics of au
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6ed4cc0a587ea7c28410411a382a721
https://doi.org/10.1136/annrheumdis-2020-eular.6091
https://doi.org/10.1136/annrheumdis-2020-eular.6091
Autor:
A. Castillo Ortiz, E. Alvarez Hernandez, X. Jimenez Jimenez, Esther Zamora, F. Irazoque-Palazuelos, David Vega-Morales, S. Duran Barragan, M. Rull-Gabayet, Mónica Martínez-Martínez, B. E. Zazueta, D. Cervantes-Rosete, D. Alpizar-Rodriguez, C. F. Pacheco Tena, E. Martin-Nares, M. Vázquez-Del Mercado Espinosa, D. X. Xibille Friedmann, J. F. Moctezuma-Ríos, T. S. Rodriguez-Reyne, A. Barragán-Garfías
Publikováno v:
Annals of the Rheumatic Diseases. 80:905.2-906
Background:COVID-19 outcomes in Mexican patients with rheumatic diseases (RDs) in comparison to general population patients are unknown.Objectives:To compare mortality and hospitalization of COVID-19 patients with RDs and those without.Methods:We inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcb362a118a7d9d224e311e991695aeb
https://doi.org/10.1136/annrheumdis-2021-eular.3447
https://doi.org/10.1136/annrheumdis-2021-eular.3447
Autor:
David Vega-Morales, D. Alpizar-Rodriguez, Antonia Peña, Vázquez Mj, O. E. Muñoz-Monroy, A. Castillo Ortiz, J. C. Casasola, E. Torres Valdéz, S. Carrilo, V. Rivera Teran, Mirza Rivera, A. Ramos, S. Duran Barragan, Domingo Marrero Miranda, L. F. Valdés Corona, A. Paz, E. Zamora, F. Irazoque-Palazuelos, S. Sicsik, N. Santana, K. Alvarado, Fernando Guerrero, D. X. Xibille Friedmann, C. Zepeda
Publikováno v:
Annals of the Rheumatic Diseases. 80:559.2-560
Background:Rheumatoid arthritis (RA) is the most common autoimmune disease. Older patients treated with biologic DMARDs (bDMARDs) are at a significantly greater risk of adverse effects (AEs) [1]. However, the rate of drug discontinuation because of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00e6e57cb34d9717c3bdc96fb6d7ad7d
https://doi.org/10.1136/annrheumdis-2021-eular.3759
https://doi.org/10.1136/annrheumdis-2021-eular.3759
Publikováno v:
Annals of the Rheumatic Diseases. 80:899.3-900
Background:SARS-CoV2 infection and COVID-19 associated pneumonia are associated to a dysregulated inflammatory response known as cytokine storm and the use of cytokine inhibitors, especially those targeting IL-6, has been proposed as a therapeutic al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bc9d1782f7f706fa484d20e1b2b11fd
https://doi.org/10.1136/annrheumdis-2021-eular.3122
https://doi.org/10.1136/annrheumdis-2021-eular.3122
POS1242 FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH RHEUMATIC DISEASES AND COVID-19 IN MEXICO
Autor:
X. Jimenez Jimenez, A. Barragán-Garfías, Mónica Martínez-Martínez, O. Marquez, D. Alpizar-Rodriguez, T. S. Rodriguez-Reyne, M. E. Macias, S. Duran Barragan, F. Cobos-Villanueva, J. F. Moctezuma-Ríos, D. X. Xibille Friedmann, A. Sanchez-Rodriguez, L. V. Maya-Piña, F. Irazoque-Palazuelos, M. D. P. Cruz-Domínguez, G. Reyes, David Vega-Morales, M. Aguiar Castellanos, M. Rull-Gabayet, A. Martinez, D. Cervantes-Rosete, Esther Zamora, A. Castillo Ortiz, Lilia Andrade, C. F. Pacheco Tena, E. Martin-Nares, M. Vázquez-Del Mercado Espinosa, B. E. Zazueta, J. E. Navarro-Zarza, A. Vargas Guerrero
Publikováno v:
Annals of the Rheumatic Diseases. 80:904.1-904
Background:As of the 25th of January 2021, more than 150 thousand deaths as consequence of COVID-19 have been reported in Mexico [1]. Advanced age, male gender and comorbidities have been described as risk factors for severe disease and mortality in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c2e3b1744835325533f7fd957d363ad
https://doi.org/10.1136/annrheumdis-2021-eular.3342
https://doi.org/10.1136/annrheumdis-2021-eular.3342
Autor:
F. Aceves, S. Carrilo, N. Santana, Aníbal Castillo, Leonor Barile, J. C. Casasola, S. Sicsik, D. X. Xibille Friedmann, F. Irazoque-Palazuelos, David Vega-Morales, A. Paz, Domingo Marrero Miranda, V. Rivera Teran, J. F. Moctezuma, S. Duran Barragan, D. Alpizar-Rodriguez, C. F. Pacheco Tena, M. Pérez Rodríguez
Publikováno v:
Annals of the Rheumatic Diseases. 79:1905.1-1906
Background:Access to biosimilar drugs in Mexico started on 2014. Although biosimilar drugs safety has proved comparability to originator drugs on trials, information about its safety on real-life data is limited.Objectives:To compare safety in terms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c32b37bc0f64be3b28e24d3f3a9c91d5
https://doi.org/10.1136/annrheumdis-2020-eular.3819
https://doi.org/10.1136/annrheumdis-2020-eular.3819